title: Prognostic factors in Greek patients with small cell lung cancer (SCLC). A Hellenic Cooperative Oncology Group study.
abstract: BACKGROUND
  Prognostic factors among Greek patients with SCLC were evaluated.
  
  
  METHODS
  Data from 516 patients with SCLC treated by the Hellenic Cooperative Oncology Group were analyzed. Multivariate analysis was performed.
  
  
  RESULTS
  Complete response (CR) was achieved in 26.8% and partial response in 40.1% of patients. The median duration of response was 7.4 months, the median survival 10.5 months and the 2-year survival rate 12%. The stage of the disease was a dominant prognostic factor for survival and response. PS 0-1 was a major prognostic factor for survival, duration of response and CR. Female gender was a favorable predictor for CR. Superior vena cava syndrome was a poor prognostic factor for survival and duration of response. Weight loss and age > or = 60 were poor predictors for response. The sites of metastases affected survival, duration of response and response. Normal alkaline phosphatase was a favorable prognostic factor for survival, duration of response and response. Normal lactate dehydrogenase and thoracic irradiation were favorable prognostic factors for survival and duration of response.
authors.affiliation: Henry Dunan Hospital, 107 Mesogion Street, 11526, Athens, Greece. hecogiat@otenet.gr
authors.forename: C
authors.initials: C
authors.lastname: Christodolou
authors.forename: N
authors.initials: N
authors.lastname: Pavlidis
authors.forename: E
authors.initials: E
authors.lastname: Samantas
authors.forename: G
authors.initials: G
authors.lastname: Fountzilas
authors.forename: G
authors.initials: G
authors.lastname: Kouvatseas
authors.forename: K
authors.initials: K
authors.lastname: Pagdatoglou
authors.forename: F
authors.initials: F
authors.lastname: Palamidas
authors.forename: C
authors.initials: C
authors.lastname: Nikolaidis
authors.forename: M
authors.initials: M
authors.lastname: Angelidou
authors.forename: H P
authors.initials: HP
authors.lastname: Kalofonos
authors.forename: P
authors.initials: P
authors.lastname: Kosmidis
authors.forename: D V
authors.initials: DV
authors.lastname: Skarlos
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage; D018288:Carcinoma, Small Cell / Q000150:complications / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D002986:Clinical Trials as Topic; D005006:Ethnicity; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006115:Greece; D006801:Humans; D008175:Lung Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D011379:Prognosis; D012307:Risk Factors; D012737:Sex Factors; D013479:Superior Vena Cava Syndrome / Q000150:complications; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D005047:Etoposide; D016190:Carboplatin